U.S. stock market midday update: Analysts' bearish stance inadvertently boosts Jyong Biotech by 33.56%, intensifying volatility in the biotechnology sector?

U.S. Stock Market Midday Update Jyong Biotech rose 33.56%. Based on recent news: On December 18, analysts rated Jyong Biotech as a sell, believing there are better investment options in the market. Analysts identified five stocks that are more valuable investments than Jyong Biotech, leading to a decline in investor confidence and a drop in stock price. Source: MarketBeat No other significant news recently. The biotechnology industry has been volatile lately and requires attention. The biotechnology industry has been volatile lately and requires attention. Stocks with High Trading Volume in the Industry Insmed fell 15.45%. Based on recent key news: On December 17, Insmed announced that its Brensocatib drug failed to meet primary or secondary efficacy endpoints in a phase 2 study for chronic sinusitis patients, leading to the immediate termination of the project. This news caused the stock price to drop 17% in after-hours trading. Source: MT Newswires On December 18, Insmed's stock price plummeted 20.1% in pre-market trading to $158.50 after abandoning sinus drug development following the mid-term study failure. Jefferies and TD Cowen both lowered their target prices. Source: Reuters On December 16, Insmed was included in the Nasdaq 100 Index. Although this news provided some support for the stock price, it could not offset the negative impact of the study failure. Source: Nasdaq The biotechnology industry has been increasingly volatile lately and requires attention. Amgen fell 0.70%. Based on recent news: On December 18, HSBC raised Amgen's target price from $381 to $425 and maintained a buy rating. This move is part of the bank's outlook for the pharmaceutical industry in 2026, showing confidence in Amgen's future growth; however, the stock price did not immediately reflect this positive expectation. On December 15, analysis from MarketBeat indicated that although Amgen received a moderate buy rating, top analysts believe there are five stocks with greater investment value. This may lead to weakened investor confidence in Amgen, affecting stock performance. The pharmaceutical industry faces policy changes and competitive pressures. AbbVie rose 0.31%. Based on recent key news: On December 18, Morgan Stanley analysts maintained an overweight rating on AbbVie with a target price of $269. This move boosted market confidence in the stock, driving the price up. On December 18, HSBC analysts upgraded AbbVie to a buy rating and adjusted the target price to $265. The analysts' positive assessment further supported the upward trend in the stock price. On December 15, Bank of America lowered AbbVie's target price from $248 to $233 while maintaining a neutral rating. Despite the target price reduction, the company's fundamentals remain solid, and the stock price was not significantly affected The pharmaceutical sector outperformed the market, but risks need to be monitored. Stocks ranked among the top in industry market capitalization Gilead Sciences rose 0.25%. Based on recent key news: On December 15, Gilead Sciences announced that its experimental HIV treatment met its primary endpoint in late-stage trials. This news boosted market confidence in the company's expansion capabilities in the HIV field, driving the stock price up. On December 17, Gilead Sciences' Chief Financial Officer Andrew D. Dickinson and Chief Business Officer Johanna Mercier reported the sale of the company's common stock. Such insider trading may raise market concerns about the company's future performance, leading to stock price volatility. On December 18, Gilead Sciences appointed Keeley Wettan as Executive Vice President and General Counsel. This personnel change may have a positive impact on the future development of the company's legal compliance department, further stabilizing the stock price. Competition in the HIV treatment field is intensifying and needs to be monitored